|Page (1) of 1 - 10/03/17||email article||print page|
Voyager Therapeutics to Present at Investor Conferences in October(October 03, 2017)
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
- Chardan Gene Therapy Conference, New York City
Date: Tuesday, October 10, 2017Time: 9:00 a.m. EDT
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer
- Jefferies Gene Technology Investor Summit, New York City
Date: Thursday, October 12, 2017
Time: 3:30 p.m. EDT
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Dinah Sah, Ph.D., chief scientific officer
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyagers website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyagers pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinsons disease, a monogenic form of ALS, Huntingtons disease, Friedreichs ataxia, frontotemporal dementia, Alzheimers disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
CONTACT: Investor Relations: Matt OsborneHead of Investor Relations & Corporate [email protected] Media: Katie EnglemanPure Communications, [email protected]